Risk stratification for adverse events, such as metastasis to lymph nodes, is based only on histologic features of tumors. We aimed to compare adverse outcomes of pedunculated vs nonpedunculated T1 colorectal cancers (CRC).
risk of metastasis (adjusted OR, 0.62; 95% CI, 0.41-0.94; P [ .03), incomplete resection (adjusted OR, 0.57; 95% CI, 0.36-0.91; P [ .02), and recurrence (adjusted hazard ratio, 0.52; 95% CI, 0.32-0.85; P [ .009). Metastasis, incomplete resection, and recurrence did not differ significantly between low-risk pedunculated vs nonpedunculated T1CRCs (0.8% vs 2.9%, P [ .38; 1.5% vs 0%, P [ .99; 1.5% vs 0%; P [ .99). However, incomplete resection and recurrence were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs (6.5% vs 12.5%; P [ .007; 4.4% vs 8.6%; P [ .03).
CONCLUSIONS:
In a retrospective study of patients with T1CRC, we found pedunculated morphology to be associated independently with a decreased risk of adverse outcome in a T1CRC population at high risk of adverse outcome. Incorporating morphologic features of tumors in risk assessment could help predict outcomes of patients with T1CRC and help identify the best candidates for surgery.
Keywords: Colonoscopy; Endoscopic Mucosal Resection; Colon Cancer; Prognostic Factor.
See related editorial on page 1035.
T he frequency of early colorectal cancer (CRC) has been increasing since the introduction of national screening programs. In 2015, 48% of detected CRCs in the Dutch screening program were stage I CRCs, in line with other Western countries.
1-3 T1 colorectal cancer (T1CRC) without metastasis is the earliest form of stage I CRC and is defined as tumor growing through the muscularis mucosae into the submucosa without invading the muscularis propria. 4 Lymph node metastasis (LNM) risk of T1CRC is 8% to 14%. [5] [6] [7] [8] [9] [10] [11] [12] Therefore, most patients with T1CRC can be cured with an endoscopic resection. However, current risk models have insufficient ability to predict which patients with an endoscopically resected T1CRC should have additional surgery. 13 Complete endoscopic resection of pedunculated T1CRCs is more feasible compared with nonpedunculated T1CRCs. In addition, pedunculated T1CRCs may have a lower metastasis risk compared with nonpedunculated T1CRCs. 9, [14] [15] [16] In the present study, we evaluated the association between morphology (pedunculated vs nonpedunculated) and adverse outcome.
Methods

Study Design
We performed a multicenter retrospective cohort study. Patients with T1CRC, defined as tumor growing through the muscularis mucosae into, but not beyond, the submucosa, 17 diagnosed between January 1, 2000, and December 31, 2014, in 14 Dutch hospitals (2 academic and 12 nonacademic), were selected from The Netherlands Cancer Registry. Electronic medical records were reviewed. Patients with synchronous CRC, non-CRC-related death within 1 year, hereditary predisposition for CRC, inflammatory bowel disease, carcinoid, missing pathology or endoscopy reports, and who underwent neoadjuvant radiotherapy were excluded. In addition, patients without reported morphology in the endoscopy report were excluded.
Determinant
The determinant of interest was morphology, stratified as pedunculated vs nonpedunculated. Because closing the snare followed by dehydration and formalin fixation procedures can alter morphology, morphology was based on the endoscopist's judgement. T1CRC was considered pedunculated in case of presence of a stalk or Paris Classification 0-Ip was reported. Nonpedunculated T1CRC included flat or sessile tumors. [18] [19] [20] 
End Points
The primary composite end point was adverse outcome, defined as any of the following: LNM, distant metastasis, local recurrence, or residual tissue. We used a composite end point rather than only LNM because the surgical referral rate is known to be higher for patients with nonpedunculated T1CRCs. Restricting our analysis to patients treated with surgery (ie, patients with known N status) therefore would introduce selection bias. The end point could be reached by both endoscopically and surgically treated patients, allowing an equal comparison of pedunculated and nonpedunculated T1CRCs. LNM was defined as tumor-positive lymph nodes (LNs) in the surgical specimen. Distant metastasis was defined as metastasis to extracolonic organs confirmed with imaging or histology. Local recurrence was defined as carcinoma in biopsy tissue from the anastomosis after surgery or from the polypectomy scar after endoscopic resection. Residual tissue was defined as carcinoma in the surgical specimen after endoscopic resection, irrespective of whether endoscopic resection was macroscopically complete or not.
Secondary end points included metastasis, recurrence, and incomplete resection separately. We defined metastasis as LNM for patients who underwent surgery or distant metastasis regardless of treatment. Recurrence was defined as local recurrence or distant metastasis regardless of treatment. Incomplete resection was defined as residual tissue in the colectomy specimen after secondary surgery or local recurrence regardless of treatment.
Confounders
Clinical confounders included age, sex, tumor localization (right colon vs left colon vs rectum), and tumor size. 9, 13, [21] [22] [23] [24] The right colon was defined as the colon proximal to and including the splenic flexure and the left colon as the colon distal to the splenic flexure excluding the rectum. Histologic confounders included lymphovascular invasion (absent vs present), differentiation grade (good or moderate vs poor), and resection margins (negative [R0] vs not assessable [Rx] vs positive [R1]). R0 resection was defined as a cancer-free resection margin irrespective of distance in millimeters. In patients treated with primary endoscopy and secondary surgery, endoscopic resection margins were used and in patients treated with primary surgery, surgical resection margins were used. Although invasion depth is an acknowledged risk factor for stratification of T1CRCs into low-or high-risk groups, invasion depth was not included as a confounder because the classification for submucosal invasion depth is inherently different between pedunculated and nonpedunculated T1CRCs. 23, 25, 26 Treatment approach and LN yield were considered confounders because surgery decreases recurrence risk in high-risk T1CRC and a high LN yield has been associated with a decreased risk for recurrence. 21, 22 Patients were categorized into 3 subgroups: endoscopic resection, surgical resection with fewer than 10 LNs retrieved, and surgical resection with 10 or more LNs retrieved. Transanal endoscopic microsurgery was considered an endoscopic treatment because no lymphadenectomy was performed.
Statistical Analysis
Baseline characteristics were compared between pedunculated and nonpedunculated T1CRCs using standard descriptive statistics. In addition, the risk for adverse outcome, metastasis, recurrence, and incomplete resection between low-risk pedunculated and nonpedunculated T1CRC, and high-risk pedunculated and nonpedunculated T1CRC, was compared using descriptive statistics. T1CRCs were classified as high risk if 1 or more of the following criteria were present: (1) poor differentiation, (2) deep submucosal invasion (>1000 mm or sm2-3 for nonpedunculated; Haggitt 4 for pedunculated), (3) lymphovascular invasion, or (4) Rx/R1 resection margins, in line with current guidelines. 23, 25, 26 If all of these criteria were absent, T1CRCs were classified as low risk. If 1 of the criteria was unknown and no other high-risk factors were present, risk status was classified as unknown.
We evaluated whether morphology was associated with adverse outcome using univariable and multivariable logistic regression analyses and adjusted for confounders in a 4-step approach. First, we adjusted for clinical factors. Second, we additionally adjusted for histologic factors (lymphovascular invasion and differentiation grade). In a third step, we additionally adjusted for resection margins. We chose this approach because histologic factors were missing in a considerable number of patients. Fourth, we additionally adjusted for treatment approach. The association between morphology and the secondary end points metastasis and incomplete
What You Need To Know
Background Current histologic prediction models have insufficient discriminative ability to identify patients who benefit from surgical treatment after endoscopic resection. Although it has been suggested that pedunculated T1 colorectal cancers (T1CRCs) have a lower risk for metastasis and incomplete resection as compared with nonpedunculated T1CRCs, a direct comparison has not yet been performed and current risk stratification for surgery is based on histology only.
Findings
Pedunculated morphology was associated independently with a decreased risk for an adverse outcome (ie, lower risk for lymph node metastasis, distant metastasis, local recurrence, or residual tissue). The absolute risk for adverse outcomes in patients with pedunculated T1CRC was nearly half that of patients with nonpedunculated T1CRCs (9.3% vs 16.6%, respectively). In patients with low-risk T1CRC, defined as the absence of the following criteria: poor differentiation, deep submucosal invasion, lymphovascular invasion, and Rx/R1 resection margins, the rates of metastasis, incomplete resection, and recurrence rates did not differ significantly between pedunculated vs nonpedunculated morphology. However, incomplete resection and recurrence rates were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs.
Implications for patient care
Morphology has a promising potential to refine risk stratification in patients with T1CRC and therefore should be incorporated in future risk stratification. This study underlines that the ratio of included pedunculated and nonpedunculated T1CRCs should be taken into account when extrapolating the risk for adverse outcomes as reported in the current literature to individual patients in clinical practice, and necessitates adequate reporting of morphology type in future T1CRC studies. resection was evaluated in the same manner. The association between morphology and recurrence was evaluated with univariable and multivariable Cox regression analyses, expressed in hazard ratios (HRs) with 95% CI. We adjusted for the same confounders as the primary end point and additionally adjusted for LNM because this is a well-established risk factor for recurrence. 4, 27 The follow-up period started at the date of diagnosis and ended at the date of detection of recurrence, death, or last follow-up evaluation. We found no violation of the proportionality of the hazard assumption by examining the scaled Schoenfeld residuals.
Several confounding variables had missing values. Multivariate imputation by chained equations (10 imputation data sets, 25 iterations, healthy convergence) was performed before data analysis (package mice in R). 28 Rubin's rules were used to pool results across imputation data sets. 29 Statistical analysis was performed using IBM SPSS Statistics version 24 (SPSS, Inc, Chicago, IL) and R version 3.2.2 (RStudio, Inc, Boston, MA).
Results
Study Population
We identified 2346 patients diagnosed with T1CRC between 2000 and 2014 in participating hospitals. Of these, 1656 patients with a median follow-up time of 42.5 months (interquartile range [IQR], 18.5-77.5 mo) were eligible for analysis ( Figure 1 ). The cohort consisted of 723 pedunculated T1CRCs (43.7%) followed up for a median of 45.6 months (IQR, 20.6-80.3 mo), and 933 (56.3%) nonpedunculated T1CRCs followed up for a median of 40.9 months (IQR, 17.2-73.6 mo).
Baseline characteristics of patients with pedunculated vs nonpedunculated T1CRCs are presented in Table 1 . Compared with patients with nonpedunculated T1CRCs, patients with pedunculated T1CRCs were younger (69 vs 71 y; P < .001) and more often treated with primary endoscopy (52.8% vs 27.4%; P < .001). Moreover, pedunculated T1CRCs more often were located in the left colon (80.5% vs 44.4%; P < .001) and were smaller (20 vs 23 mm; P < .001). LN yield more often was low (<10 retrieved LNs) in patients with pedunculated T1CRCs (71.9% vs 54.7%; P < .001). The presence of lymphovascular invasion and poor differentiation did not differ significantly, however, R0 resection was achieved less often in patients with pedunculated T1CRCs (69.8% vs 75.3%; P ¼ .04). If patients underwent an endoscopic resection of T1CRC, R0 resection was achieved in 63.7% of pedunculated vs 46.9% of nonpedunculated T1CRCs.
Adverse Outcome
Adverse outcomes were observed in 13.4% (222 of 1656; 95% CI, 11.8-15.2) of patients. This concerned 93 patients with LNM, 39 with distant metastasis, 33 with local recurrences, 18 with local and distant metastasis, and 58 with residual tumor in the surgical specimen when additional surgery was performed, with 17 patients having 2 or 3 adverse oncologic events. The median time to recurrence was 23.1 months (IQR, 10.1-43.2 mo) and did not differ significantly between patients with pedunculated and nonpedunculated T1CRCs (median, 19.2 mo; IQR, 10.7-43.7 mo; median, 24.8 mo; IQR, 9.8-43.2 mo; respectively; P ¼ .77).
Adverse outcomes were observed in 9.3% (67 of 723; 95% CI, 7.4-11.6) of patients with pedunculated vs 16.6% (155 of 933; 95% CI, 14.4-19.1) of patients with nonpedunculated T1CRCs. Adverse outcomes did not differ significantly between low-risk pedunculated vs low-risk nonpedunculated T1CRCs (2.3% vs 2.9%; P ¼ .99), however, adverse outcomes were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs (14.0% vs 21.2%; P ¼ .01) ( Table 2) .
In univariable analysis, pedunculated morphology was associated with a decreased risk for adverse outcome (unadjusted odds ratio [OR], 0.51; 95% CI, 0.38-0.70; P < .001). After adjusting for clinical variables, histologic variables, resection margins, and treatment approach, the pedunculated morphology remained independently associated with a decreased risk for adverse outcome (adjusted OR, 0.59; 95% CI, 0.42-0.83; P ¼ .003).
Metastasis, Incomplete Resection, and Recurrence
Metastasis was observed in 8.5% (141 of 1656; 95% CI, 7.2-10.0) of patients: 93 with LNM and 57 with Metastasis, incomplete resection, and recurrence did not differ significantly between low-risk pedunculated vs nonpedunculated T1CRCs (0.8% vs 2.9%, P ¼ .38; 1.5% vs 0%, P ¼ .99; and 1.5% vs 0%, P ¼ .99; respectively). However, incomplete resection and recurrence rates were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs (6.5% vs 12.5%, P ¼ .007; 4.4% vs 8.6%, P ¼ .03; respectively) ( Table 2) .
In univariable analysis, pedunculated morphology was associated with a decreased risk for metastasis (unadjusted OR, 0.52; 95% CI, 0.36-0.76; P < .001), decreased risk for incomplete resection (unadjusted OR, 0.55; 95% CI, 0.36-0.83; P ¼ .005), and decreased risk for recurrence (unadjusted HR, 0.54; 95% CI, 0.35-0.85; (Table 3 ). Moreover, after adjusting for the same variables plus LNM, the pedunculated morphology remained independently associated with a decreased risk for recurrence (adjusted HR, 0.52; 95% CI, 0.32-0.85; P ¼ .009) ( Table 3) .
Discussion
This study presents a large-scale comparison of adverse outcomes between T1CRCs with different morphology. We observed an almost 2-fold lower adverse outcome rate in patients with pedunculated compared with nonpedunculated T1CRCs (9.3% vs 16.6%), and pedunculated T1CRCs had a favorable outcome even after adjusting for clinicopathologic confounders. We observed no significant differences in adverse outcomes between low-risk pedunculated and nonpedunculated T1CRCs. Our study thereby does not support that traditionally defined low-risk sessile T1CRCs must undergo surgery because of an intrinsically aggressive behavior.
The favorable outcome in patients with pedunculated T1CRCs implies that the reported risk of adverse outcomes in T1CRC cohorts is influenced by the ratio of included pedunculated and nonpedunculated T1CRCs. We should take this into account when extrapolating the risk for adverse outcomes as reported in the current literature to individual patients in clinical practice. Moreover, this necessitates adequate reporting of morphology type together with stratified adverse outcome rates in future T1CRC studies. In addition, the combined positive predictive value of current histologic markers is as low as 10% to 15%, which means that 85% to 90% of patients undergo major surgery without any clinical benefit. 13 Our results suggest that morphology may refine risk stratification, helping to expand the proportion of T1CRC patients treated with endoscopic resection.
Although patient numbers were low in the low-risk nonpedunculated T1CRC group, our study suggests that risk for adverse outcomes is similar in pedunculated and nonpedunculated low-risk T1CRCs. A low percentage of low-risk nonpedunculated T1CRCs is in line with previous studies. 9, 30 Several factors have contributed to this. First, if only 1 of the high-risk factors was absent, patients could not be classified as low risk. Adverse outcome rates in the unknown group are between the rates found in the low-and high-risk groups, suggesting that the actual number of patients with low-risk T1CRC was higher. Second, achieving a R0 resection is more difficult in nonpedunculated compared with pedunculated T1CRCs. 31 Finally, current risk stratification is limited. Our study group recently developed a new model to better predict the need for adjuvant surgery in patients with pedunculated T1CRCs. 32 With this model, a higher number of pedunculated T1CRCs could be classified as low risk compared with conventional models (68% vs 35%). This may be a first step toward a T1CRC risk assessment taking morphology into account. NOTE. T1CRCs were classified as high-risk T1CRCs if 1 or more of the following criteria were present: (1) poor differentiation, (2) deep submucosal invasion (>1000 mm or sm2-3 for nonpedunculated T1CRCs, Haggitt 4 for pedunculated T1CRC), (3) lymphovascular invasion, (4) Rx/R1 resection margins. When all these factors were absent, it was considered a low-risk T1CRC. The unknown risk group concerns T1CRCs in which 1 of these histologic features was unknown and no high-risk factors were present. T1CRC, T1 colorectal cancer. 9 This study, however, reviewed several small nonconsecutive cohorts. In addition, no adjustment for confounders was performed and treatment approach was not taken into account. A more recent population-based study including 411 patients with T1CRC diagnosed between 1982 and 2011, reported a 5-year cumulative recurrence rate of 5.2% for pedunculated and 6.3% for nonpedunculated T1CRCs (P ¼ .66). 33 However, this comparison was based on only 15 recurrences vs 90 recurrences in our study. In addition, inclusion bias may have occurred because only endoscopic benign-appearing T1CRCs were included. A study of the Scottish Surgical Research Group on 485 patients with T1CRCs, which were identified through the screening program between 2000 and 2012, found no significant difference in adverse outcomes between pedunculated and nonpedunculated T1CRCs after adjustment for confounders. 34 However, this study only included patients who underwent endoscopic resection (followed by segmental resection or not), which may have led to exclusion of nonpedunculated high-risk T1CRCs unfit for endoscopic resection in particular, leading to an underestimation of adverse outcomes in the nonpedunculated T1CRC group.
This study had some limitations. Adequate histologic diagnosis of pedunculated T1CRC is challenging. 35, 36 A recent histologic review of a subgroup of 128 pedunculated T1CRCs from our cohort by pathologists with special expertise in gastrointestinal pathology showed that approximately 10% of cases were overstaged (ie, T1CRC diagnosis was revised as pseudo-invasion or high-grade dysplasia). 37 This may underestimate the adverse outcomes of pedunculated T1CRCs in our cohort. However, our previous study did not evaluate the percentage of missed T1CRCs diagnosed histologically as premalignant lesions. In addition, pseudoinvasion and biopsy-related displaced epithelium simulating malignancy also have been described in nonpedunculated T1CRCs, which might balance the potential underestimation in pedunculated T1CRCs. 38 Finally, differentiating T1CRC from its precursor lesions is an up-to-date challenge and our cohort reflects daily clinical practice. 36 Because of the retrospective design, another limitation of this study was that some variables had a large number of missing data. As a result, we had to classify a relatively large number of T1CRCs as having an unknown risk status (41%). To minimize bias introduced by missing data in the regression analysis, we performed multiple imputations. Furthermore, we performed the regression analysis in a stepwise approach, in which we first adjusted for clinical variables with a low missing rate followed by adjustment for histologic variables with a higher missing rate.
In conclusion, pedunculated morphology was associated independently with a decreased risk for adverse outcomes and the absolute risk for adverse outcomes in patients with pedunculated T1CRCs was nearly half that of patients with nonpedunculated T1CRCs. In patients with low-risk T1CRCs, rates of metastasis, incomplete resection, and recurrence rates did not differ significantly between pedunculated vs nonpedunculated morphology. However, incomplete resection and recurrence rates were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs. Our results suggest that morphology has a promising potential to refine risk stratification in patients with T1CRCs and encourage incorporation of morphology in risk stratification. Furthermore, our study underlines that the ratio of included pedunculated and nonpedunculated T1CRCs should be taken into account when extrapolating the risk for adverse outcomes as reported in the current literature to individual patients in clinical practice and necessitates adequate reporting of morphology in future T1CRC studies.
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